Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for three new employees. The compensation committee approved restricted stock unit (RSU) awards for 6,338 shares and stock options for 29,575 shares under the company's Equity Inducement Plan.
The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new employee recruitment.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione di sviluppo e produzione su contratto (CDMO), ha annunciato concessioni di azioni come incentivo per tre nuovi dipendenti. Il comitato per la retribuzione ha approvato assegnazioni di unità azionarie vincolate (RSU) per 6.338 azioni e opzioni su azioni per 29.575 azioni nell'ambito del Piano di Incentivo Azionario dell'azienda.
Le RSU matureranno completamente dopo tre anni, mentre le opzioni su azioni matureranno per un terzo dopo il primo anno e per 1/36 ogni mese successivo. Le opzioni hanno una durata di sette anni e un prezzo di esercizio pari al Valore di Mercato Corrente. Queste concessioni sono state effettuate in conformità alla Regola Nasdaq 5635(c)(4) come incentivo per il reclutamento di nuovi dipendenti.
Lifecore Biomedical (NASDAQ: LFCR), una organización de desarrollo y fabricación por contrato (CDMO), ha anunciado concesiones de acciones como incentivo para tres nuevos empleados. El comité de compensación aprobó premios en unidades restringidas de acciones (RSU) por 6,338 acciones y opciones sobre acciones por 29,575 acciones bajo el Plan de Incentivos de Acciones de la empresa.
Las RSU se consolidarán completamente después de tres años, mientras que las opciones sobre acciones se consolidarán en un tercio después del primer año y 1/36 mensualmente a partir de entonces. Las opciones tienen un plazo de siete años y un precio de ejercicio al Valor Justo de Mercado. Estas concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivo para la contratación de nuevos empleados.
Lifecore Biomedical (NASDAQ: LFCR)는 계약 개발 및 제조 조직(CDMO)으로서, 세 명의 신입 사원을 위한 주식 유인 보상을 발표했습니다. 보상 위원회는 회사의 주식 유인 계획에 따라 6,338주의 제한 주식 단위(RSU) 보상와 29,575주의 스톡 옵션을 승인했습니다.
RSU는 3년 후 완전히 권리 확정되며, 스톡 옵션은 첫 해 후 3분의 1이 권리 확정되고 이후 매월 1/36씩 권리 확정됩니다. 스톡 옵션의 유효 기간은 7년이며 행사가격은 공정 시장 가치입니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 신입 사원 채용 유인으로 제공되었습니다.
Lifecore Biomedical (NASDAQ : LFCR), une organisation de développement et de fabrication sous contrat (CDMO), a annoncé des attributions d'actions incitatives pour trois nouveaux employés. Le comité de rémunération a approuvé des attributions d'unités d'actions restreintes (RSU) pour 6 338 actions et des options d'achat d'actions pour 29 575 actions dans le cadre du Plan d'incitation en actions de la société.
Les RSU seront entièrement acquises après trois ans, tandis que les options d'achat d'actions seront acquises pour un tiers après la première année puis à raison de 1/36 chaque mois par la suite. Les options ont une durée de sept ans et un prix d'exercice à la juste valeur marchande. Ces attributions ont été effectuées conformément à la règle Nasdaq 5635(c)(4) en tant qu'incitation au recrutement de nouveaux employés.
Lifecore Biomedical (NASDAQ: LFCR), ein Vertragsentwicklungs- und Herstellungsunternehmen (CDMO), hat Aktienanreiz-Zuweisungen für drei neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte Restricted Stock Unit (RSU)-Zuweisungen für 6.338 Aktien und Aktienoptionen für 29.575 Aktien im Rahmen des Aktienanreizplans des Unternehmens.
Die RSUs werden nach drei Jahren vollständig unverfallbar, während die Aktienoptionen zu einem Drittel nach dem ersten Jahr und anschließend monatlich zu 1/36 unverfallbar werden. Die Aktienoptionen haben eine Laufzeit von sieben Jahren und einen Ausübungspreis zum Fair Market Value. Diese Zuteilungen erfolgten gemäß Nasdaq Listing Rule 5635(c)(4) als Anreiz für die Rekrutierung neuer Mitarbeiter.
- None.
- None.
CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common stock to three newly hired employees. The awards will be granted on July 11, 2025, or the first day of employment, whichever is later, pursuant to offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.
The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.
The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. Each of the RSU and stock option awards is governed by an award agreement and the Inducement Plan.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com
FAQ
What equity inducement grants did Lifecore Biomedical (LFCR) announce?
What are the vesting terms for Lifecore's (LFCR) new equity grants?
When will the Lifecore (LFCR) inducement grants be awarded?
Why did Lifecore Biomedical (LFCR) issue these equity grants?
